This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: The Penn State Research Foundation. Active years: 2014-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014-2015
Title: Thomas T. Morgan: Innovator in Nanoparticle Technology
Introduction
Thomas T. Morgan is a notable inventor based in Pepperell, MA (US). He has made significant contributions to the field of nanoparticle technology, particularly in the development of bioconjugated calcium phosphosilicate nanoparticles. With a total of 2 patents, his work focuses on enhancing targeted therapies for cancer treatment.
Latest Patents
Morgan's latest patents include innovative methods for the bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo. This technology involves bioconjugating non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) to targeting molecules specific to certain cells. The CPNPs are designed to be stable at normal physiological pH, allowing for the compartmentalization of chemotherapy and imaging agents within the nanoparticles. This method not only protects the agents from environmental interactions but also ensures their release at intracellular pH, thereby delivering a higher concentration of the agent directly to the targeted cells.
Another significant patent involves the use of nano-encapsulated photosensitizers for in vivo photodynamic therapy of cancer. By encapsulating photosensitizers in calcium phosphate nanoparticles, the half-life and absorption of these agents into target tissues are significantly enhanced. This innovation increases the photostability and photoefficiency of the photosensitizers, making them highly effective for tumor treatment and imaging.
Career Highlights
Thomas T. Morgan is affiliated with the Penn State Research Foundation, where he continues to advance his research in nanoparticle technology. His work has the potential to revolutionize cancer treatment by providing more effective and targeted therapeutic options.
Collaborations
Morgan has collaborated with esteemed colleagues such as James H. Adair and Mark Kester, contributing to the advancement of research in his field.
Conclusion
Thomas T. Morgan's innovative work in nanoparticle technology exemplifies the potential of targeted therapies in cancer treatment. His contributions through his patents are paving the way for more effective medical solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile